Quantification of T-cell and B-cell replication history in aging, immunodeficiency, and newborn screening by Verstegen, R.H.J. (Ruud H.J.) et al.
ORIGINAL RESEARCH
published: 29 August 2019
doi: 10.3389/fimmu.2019.02084
Frontiers in Immunology | www.frontiersin.org 1 August 2019 | Volume 10 | Article 2084
Edited by:
Antonio Condino-Neto,
University of São Paulo, Brazil
Reviewed by:
Shigeaki Nonoyama,
National Defense Medical
College, Japan
Roshini Sarah Abraham,
Nationwide Children’s Hospital,
United States
*Correspondence:
Menno C. van Zelm
menno.vanzelm@monash.edu
Specialty section:
This article was submitted to
Primary Immunodeficiencies,
a section of the journal
Frontiers in Immunology
Received: 14 June 2019
Accepted: 19 August 2019
Published: 29 August 2019
Citation:
Verstegen RHJ, Aui PM, Watson E,
De Jong S, Bartol SJW, Bosco JJ,
Cameron PU, Stirling RG, de Vries E,
van Dongen JJM and van Zelm MC
(2019) Quantification of T-Cell and
B-Cell Replication History in Aging,
Immunodeficiency, and Newborn
Screening. Front. Immunol. 10:2084.
doi: 10.3389/fimmu.2019.02084
Quantification of T-Cell and B-Cell
Replication History in Aging,
Immunodeficiency, and Newborn
Screening
Ruud H. J. Verstegen 1,2,3, Pei M. Aui 4,5, Eliza Watson 4,5, Samuel De Jong 4,
Sophinus J. W. Bartol 1, Julian J. Bosco 5,6, Paul U. Cameron 5,6, Robert G. Stirling 5,6,
Esther de Vries 7,8, Jacques J. M. van Dongen 9 and Menno C. van Zelm 1,4,5,6*
1Department of Immunology, Erasmus MC, University Medical Centre, Rotterdam, Netherlands, 2Division of Rheumatology,
Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 3Division of Clinical Pharmacology and
Toxicology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 4Department of Immunology
and Pathology, Monash University, Melbourne, VIC, Australia, 5 The Jeffrey Modell Diagnostic and Research Centre for
Primary Immunodeficiencies, Melbourne, VIC, Australia, 6Department of Allergy, Immunology and Respiratory Medicine, The
Alfred Hospital, Melbourne, VIC, Australia, 7 Tranzo, Scientific Center for Care and Welfare, Tilburg University, Tilburg,
Netherlands, 8 Laboratory for Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands,
9Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, Netherlands
Quantification of T-cell receptor excision circles (TRECs) has impacted on human T-cell
research, but interpretations on T-cell replication have been limited due to the lack of a
genomic coding joint. We here overcome this limitation with multiplex TRG rearrangement
quantification (detecting ∼0.98 alleles per TCRαβ+ T cell) and the HSB-2 cell line with
a retrovirally introduced TREC construct. We uncovered <5 cell divisions in naive and
>10 cell divisions in effector memory T-cell subsets. Furthermore, we show that TREC
dilution with age in healthy adults results mainly from increased T cell replication history.
This proliferation was significantly increased in patients with predominantly antibody
deficiency. Finally, Guthrie cards of neonates with Down syndrome have fewer T and B
cells than controls, with similar T-cell and slightly higher B-cell replication. Thus, combined
analysis of TRG coding joints and TREC signal joints can be utilized to quantify in vivo
T-cell replication, and has direct applications for research into aging, immunodeficiency,
and newborn screening.
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INTRODUCTION
Adaptive immunity is a critical component of the vertebrate immune system and is represented
cellularly by B- and T-lymphocytes. Their crucial roles are illustrated in patients with inborn errors
of immunity (IEI) (1). For example, patients with severe combined immunodeficiency (SCID)
primarily lackmature T cells resulting in a lethal immunodeficiency if untreated (2). Predominantly
antibody deficiency (PAD) is more common (3), and infectious complications in these patients can
be managed with immunoglobulin replacement and prophylactic antibiotics. Still, about 68% of
patients develop non-infectious complications, including autoimmunity and malignancies, which
lead to high morbidity and early mortality (4–6). Hence, there is a need for early diagnosis of both
severe and milder forms of IEI, as well as reliable markers that could predict future complications.
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Similar to all blood cells, B and T lymphocytes are
continuously produced throughout life. Progenitor B and T
cells in bone marrow and thymus, respectively, generate unique
antigen receptors through genomic rearrangements of their
immunoglobulin (Ig) and T-cell receptor loci. In this process,
coding joints are formed on chromosomes, and signal joints
on circular excision products that are stably present in the cell,
but are not replicated during cell divisions (7). Newly-formed T
cells carry T-cell receptor excision circles (TRECs), whereas in
memory T-cell populations these are extremely diluted following
cell divisions. As such, TRECS are markers for thymic output
(8). Indeed, PCR-based quantitative detection of TRECs has been
applied to examine the effects of novel antiviral therapies on the
thymic output in patients withHIV infection (8, 9), and following
stem cell transplantation (10). Furthermore, TREC detection is
currently utilized in many countries world-wide for newborn
screening of SCID (11, 12).
More recently, we have introduced the use of Ig kappa deleting
recombination excision circles (KRECs) of intronRSS-Kde
rearrangements to examine B-cell replication (13). Analogous to
TRECs, KREC quantification has been incorporated in several
newborn screening protocols to detect absence of B cells for
identification of X-linked agammaglobulinemia (XLA) and B-
cell negative SCID cases (14, 15). The intronRSS-Kde coding
joints remain stably present in the genome of mature B cells
(16, 17). As a result, the ratio of these genomic coding joints to
KREC signal joints is a direct measure for the average number
of cell divisions a population of B cells has undergone (13).
This accurate quantification has enabled delineation of T-cell
dependent and – independent B-cell responses (18), as well as
abnormal proliferation of B-cell subsets in common variable
immunodeficiency (CVID; a form of PAD) (19) and Down
syndrome (20).
In contrast to intronRSS-Kde coding joints, nearly all δREC-
ψJα coding joints are removed from the genome in thymocytes
during subsequent Vα-Jα gene rearrangements (21, 22). As a
result, these cannot be used as a reliable marker for T-cell input,
which complicates the use of TRECs to accurately determine
T-cell replication history (23). We here present the means to
overcome these limitations through the use of a multiplex PCR
assay, which detects Vγ-Jγ gene rearrangement coding joints
that are stably present in TCRαβ expressing T cells. Together
with a newly generated TREC-containing cell line, these can
be used to accurately quantify T-cell replication history. We
describe accurate replication histories of naive and memory T
cell subsets, enhanced T-cell replication with aging and abnormal
T-cell replication in PAD patients. Finally, Vγ-Jγ and intronRSS-
Kde coding joints can be reliably quantified from Guthrie cards
and might form the basis of a second-tier test for absence of
TRECs and/or KRECs in neonatal screening for IEI.
MATERIALS AND METHODS
Research Subjects and Ethics
All studies were conducted in accordance with the declaration
of Helsinki. Blood samples from adult patients with XLA
or genetically-undefined PAD, as well as healthy adults were
obtained after written informed consent was provided. Buffy
coats were obtained from anonymous donors from the Australian
Red Cross. These studies were approved by the human ethics
committees of The Alfred Hospital (109/15) and Monash
University (MEC# CF15/771 and 2016-0289).
Stored Guthrie cards of 107 Dutch anonymous controls
and 84 children with Down syndrome, prepared ∼3–5 days
after birth, were collected after obtaining parental consent (24).
All Guthrie cards had been stored at room temperature for
3–9 years. This study was approved by the Medical Ethical
Committee “METOPP” employed by the Jeroen Bosch Hospital,
the Netherlands.
Generation of Control Cell Lines for the
TREC-Assay
A human TREC signal joint was PCR amplified in two parts
from genomic DNA of thymocytes to introduce a BamHI
restriction site 63 bp downstream of the signal joint, and
subsequently cloned into the retroviral LZRS-IRES-lyt2 vector
(Figure 1A). The LZRS-TREC construct was transfected into
the Phoenix amphotropic packaging cell line using Fugene-6
(Roche Molecular Biochemicals, Branchbury, NY). Stable high-
titer producer clones were selected with puromycin (1µg/ml).
The U698-DB01 pre-B-cell line (13, 25) and the HSB-2 immature
T cell line (26) were cultured for several days in RPMI 1640
medium containing 10% FCS and antibiotics before transduction
using Retronectin-coated Petri dishes (Takara, Shiga, Japan) and
recombinant retrovirus containing supernatant for 2 days, with
daily replenishing of retroviral supernatant. Cells expressing
mouse CD8 (from the lyt2 insert) were single-cell sorted using
a FACSAriaI cell sorter (BD Biosciences). Individual clones were
selected for dim mCD8 expression suggesting a single genomic
integration, and subsequently subjected to real-time quantitative
PCR to confirm the single-copy integration (see below).
Isolation of T-Cell Subsets From Human
Blood
Post-Ficoll mononuclear cells from blood bank donors were
stored in 10% DMSO in liquid nitrogen prior to use. Using
magnetic bead-based positive selection, CD4+ T cells were
separated from thawed samples, followed by positive selection
for CD8+ T cells (Dynabeads; Thermo Fisher). Both T-cell
fractions were stained with fluorochrome-conjugated antibodies
(Table S1) prior to sort-purification of four CD4+ and four
CD8+ T-cell subsets on a FACSAriaI (BD Biosciences).
DNA Extraction From Full Blood, Cell
Lines, T-Cell Subsets, and Guthrie Cards
Genomic DNA was isolated from 200 µl whole blood of adult
controls and antibody-deficient patients using a whole blood
DNA extraction kit (Sigma-Aldrich) and eluted in 200 µl MilliQ.
A genomic DNA Miniprep kit (Sigma-Aldrich) was used to
isolate DNA from cultured cell lines and sort-purified T-cell
subsets. DNA from 3 millimeter punches of Guthrie cards was
isolated using the Sigma Genelute DNA Kit, according to the
manufacturer’s instructions and eluted in 100 µl MilliQ.
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FIGURE 1 | Generation of TREC signal joint containing cell lines. (A) Schematic overview of KREC and TREC constructs. Colored triangles depict RSS, fragment sizes
(in bp) are depicted below the constructs, restriction sites: B, BamHI; E, EcoRI; S, SalI; X, XhoI. (B) Genetic composition of U698-DB01 and (C) HSB-2 TREC cell lines.
Real-Time Quantitative PCR (RQ-PCR)
Independent RQ-PCR reactions were performed in duplicate for
the albumin, TREC, KREC, intronRSS-Kde, ψJα_germline, and
TRG assays. All experiments with whole blood and T-cell subset
DNA were performed in a total mixture of 15 µl containing
TaqMan GE Mastermix (Thermo Fisher Scientific), 540 nM of
each primer (180 nM in case of multiplex mixtures), 60 nM of
each 6-FAM/ZEN/Iowa Black labeled probes (Integrated DNA
Technologies) and were run on the QuantStudio 6 Flex (Thermo
Fisher Scientific). Five microliter of DNA eluate from Guthrie
cards were run in RQ-PCRmixtures of 25 µl containing TaqMan
Universal MasterMix (Applied Biosystems, Foster City, CA),
900 nM of each primer (300 nM in case of multiplex mixtures),
100 nM of each FAM-TAMRA labeled probe, 0.4 ng BSA, and
were run on the StepOnePlus system (Life Technologies). The
primers and probes are listed in Table S2. Total DNA input per
reaction was generally between 30 and 200 ng and only samples
with duplicates differing<1 CT were included in the calculations.
Calculations
The difference in CT values between albumin and either the
intronRSS-Kde and TRG coding joints or the intronRSS-Kde and
δREC-ψJα signal joints were used to calculate the frequencies of
cells carrying these rearrangements in unpurified leukocytes. To
correct for any technical variation (efficiency) of the independent
PCR reactions, the assays were run in parallel on the U698-DB01
and HSB-2 TREC cell lines. As the U698-DB01 cell line contains
one intronRSS-Kde coding joint and one signal joint per genome
(Figure 1B), and the HSB-2 cell line contains one δREC-ψJα
signal joint per genome (Figure 1C), the frequency of cells in a
sample containing these was calculated as follows:
2
[
(CTalbumin−CTrearrangement)sample−(CTalbumin−CTrearrangement)cell line
]
·100%
Because the HSB-2 TREC cell line contains two TRG coding
joints per genome (Figure 1C), the outcome of the equation
above wasmultiplied by 2 to obtain the frequency of T cells rather
than the frequency of rearranged TRG alleles per haplotype.
Absolute copy numbers were calculated with the assumption
that the DNA content in human cells is 6.6 pg/cell (27, 28). We
did not correct for the additional chromosome 21 in patients with
Down syndrome (relative weight contribution <2%).
The difference in CT values between the intronRSS-Kde
coding and signal joints, and the TRG coding and TREC signal
joints are directly related to the replication history of B cells and
T cells, respectively. Taking into account the technical variation,
the replication histories were calculated as follows:
B− cell replication :
(
CTKREC − CTintronRSS−Kde
)
sample
−
(
CTKREC − CTintronRSS−Kde
)
cell line
and
T− cell replication :
(
CTTREC − CTTRG
)
sample
−
(
CTTREC − (CTTRG + 1)
)
cell line
As indicated, the formula to calculate T-cell replication corrects
for the presence of 2 TRG alleles per genome vs. only 1 TREC
allele per genome.
Statistics
Statistical analyses were performed using the Mann-Whitney test
for comparing unpaired samples and the Spearman R test for
correlation analysis as indicated in the figure legends (GraphPad
Prism 8.2.0 for Mac). Correlations were compared using Fisher r
to z test. A p < 0.05 was considered statistically significant.
RESULTS
Development of a Multiplex TRG Assay to
Quantify T Cells in Blood
In contrast to the intronRSS-Kde rearrangement in B cells,
the δREC-ψJα rearrangement in T cells is not an end-
stage rearrangement, since the coding joint is removed from
the genome during subsequent Vα-Jα gene rearrangements
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(Figure 2A) (23). Consequently, it is not possible to use the
δREC-ψJα rearrangement for T-cell quantification or to calculate
T-cell proliferation in combination with TRECs. To overcome
this limitation, we designed a multiplex RQ-PCR assay to amplify
TRG gene rearrangements. This locus was chosen because it is
rearranged in nearly all T-cell progenitors, it is both a one-step
and an end-stage rearrangement (not deleted from the genome),
and carries limited numbers of V and J genes (Figure 2B) (29,
30). In the design, detection of the Jγ1.2 gene was omitted as
this is specifically used in TCRγδ-expressing T cells, which hardly
undergo δREC-ψJα rearrangements (30).
Individual primer combinations were tested for similar
efficiencies using genomic DNA from multiple T-cell lines that
had rearranged distinct Vγ and Jγ genes (Table S3) (31). The
final combination was tested on DNA from purified TCRαβ+
and TCRγδ+ T cells (Figures 2C,D). In line with previous
observations (30), theψJα gene was deleted in nearly all TCRαβ+
T cells, whereas it was still abundant in TCRγδ+ T cells. The new
TRG assay detected 0.98 TRG gene rearrangements per TCRαβ+
T cell, whereas only 0.55 in TCRγδ+ T cells. Importantly, the
TRG counts correlated significantly with absolute T-cell counts,
and the intronRSS-Kde coding joints with absolute B-cell counts
(Spearman r = 0.3473, p = 0.0070, and Spearman r = 0.4172, p
= 0.0010, respectively; Figure S1).
Cell Line Controls for TREC Analysis
In our previous studies, we introduced an intronRSS–Kde signal
joint construct into the genome of the U698-M cell line using
retroviral transduction (Figure 1B) (13). As this cell line already
contained one intronRSS–Kde coding joint and two albumin
gene copies per genome, it could be used as technical control
for the ratio of coding joints and signal joints to study B-cell
proliferation, as well as the quantification of B cells in a mixture
population. To enable similar technical correction for studies
using TRECs, we inserted a ψJα-δREC signal joint construct in
the HSB-2 cell line that contains a ψJα-δREC coding joint as
well as two Vγ-Jγ coding joints that were amplified by the TRG
assay (Figures 1C, 2).
T-Cell Replication in Healthy Controls
Having established the TRG assay and HSB-2 TREC control
cell line, these were utilized to examine the replication histories
of naive and memory/effector CD4+ and CD8+ T-cell subsets
obtained from healthy controls (Figure 3A). Within CD4+ T
cells, the CD31+ recent thymic emigrants (RTE) had undergone
a median of 4.7 cell divisions and naive cells showed 6.5 cell
divisions (Figure 3B). The antigen-experienced central memory
(Tcm) and TemRO T cells, had increased levels, up to 10.8 and
9.5 cell divisions, respectively.
A
δRec-ψJα
excision circle
Vα-Jα
excision circle
// // +
+
Vα Vδ1 Vα δRec Vδ2-Dδ2-Jδ1 Vδ3
α PCR
ψJα PCR
Jα
Cα
Jδ
Cδ
// //
// //
// // //
//24 3
δRec-ψJα rearrangement
(TCRD deletion)
Vα-Jα rearrangement
Vα-Jα
coding joint
// //
δR
e
c
-ψ
J
α
//
//
//
Jα
δRec-ψJ
V
δ2
-D
δ2
-J
δ1
Vδ
3
Jδ
2
4
3
//
Cδ
TREC
D
αβ T cells γδ T cells
1.1
1.0
0.1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.0
a
lle
le
s
/c
e
ll
B
Vγ VI γII VγIII Vγ JVI γ2Jγ1
Vγ2 Vγ3 Vγ4 Vγ5 ψVγ7 Vγ8 Vγ9 Vγ10 Vγ11 1.1 1.2 1.3 2.1 2.3Cγ1 Cγ2
Vγ8-Jγ1.3 rearrangement
+
Vγ-Jγ
coding joint
Vγ-Jγ
signal joint
TRG locus
C
TRG locus
Vγ forward mix
Jγ reverse
mix
Jγ probe mix
TRGV TRGJ
TCRAD locus
FIGURE 2 | Development of a multiplex TRG PCR to quantify Vγ-Jγ coding joints as a marker for T cells. (A) Sequential rearrangements in the TCRAD locus.
Following V(D)J recombination of TCRD, the whole locus is then deleted in the αβ+ T-cell lineage, predominantly by δREC–ψJα rearrangements. The rearrangements
give rise to a δREC–ψJα signal joint on an excision circle (TREC) and a δREC–ψJα coding joint in the genome. The coding joint is deleted from the genome by TCRA
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Schematic overview of the multiplex TGR PCR assay, which contains 4 Vγ forward primers, 2 Jγ reverse primers and 2 Jγ probes (See Table S2). (D) Mean number
of rearranged TRG alleles per cell detected by multiplex TRG RQ-PCR assay in purified TCRαβ+ and TCRγδ+ T cells. The reduced detection in TCRγδ+ T cells is the
result of our deliberate decision to omit detection of the frequently utilized Jγ1.2 gene in TCRγδ+ T cells.
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FIGURE 3 | Replication histories of T-cell subsets in healthy controls. (A) Flow cytometric representation of T-cell differentiation stages. T-cell subsets were
sort-purified based on the indicated gating strategy. (B,C) Schematic representation of CD4+ and CD8+ T-cell maturation and replication histories of the purified
subsets. RTE, recent thymic emigrants; Tcm, central memory T cell; Tnaive, naive T cell; TemRO and TemRA, terminally differentiated effector memory T cell. The
Mann-Whitney U test was used for statistical analysis: *p < 0.05; **p < 0.01; ***p < 0.001.
Naive CD8+ T cells showed a similar replication history as
CD31+CD4+ naive T cells with 4.7 cell divisions (Figure 3C).
These levels were significantly higher in Tcm cells with 7.1 cell
divisions, and even more in the CCR7- TemRO and TemRA
subsets with 10.6 and 12.2 cell divisions, respectively. Thus,
in line with B-cell biology (13), the replication history of
antigen-experienced T cells is significantly higher than in naive
T-cell subsets.
Contributions of Proliferation to
Age-Associated Decline in TRECs
We examined TREC, TRG as well as the intronRSS-Kde and
KREC assays in a cohort of 59 healthy controls (median
age 31 years, range 20–63; Figure 4). Similar to Zubakov
et al. (32), we found a significant decline in TRECs with
age (r = −0.3552, p = 0.0058). The TRG copy numbers
of controls increase with age (r = 0.2621, p = 0.0449),
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the donor. (B) Correlation plots of intronRSS-Kde, KREC and B-cell replication history. Data were obtained from 59 healthy controls. Spearman r was used for
statistical analysis.
resulting in a significant increase of cell divisions with age
(r= 0.5574, p < 0.0001).
The copy numbers of intronRSS-Kde, KRECs and B-cell
replication history were not significantly correlated with age
(Figure 4B). Thus, B-cell homeostasis changes minimally with
aging, whereas the decline in TRECs with aging for the most part
is the result of an increased T-cell replication history.
Assessment of T-Cell Replication in
Predominantly Antibody Deficiency
Quantification of TRECs and KRECs has been utilized before to
subclassify patients with an antibody deficiency syndrome (33).
As no coding joint assays were performed, it remains unclear
what the contribution was of proliferation to the findings of
abnormally low TRECs and KRECs. Therefore, we here applied
our assays to 9 patients with genetically confirmed XLA and
42 patients with PAD (Table 1), who were subdivided in two
phenotypical categories: infections-only (n = 14) and non-
infectious complications (n= 28) (5, 6).
IntronRSS-Kde and KREC copy numbers in patients with
XLA were low or undetectable. The B-cell replication history
could therefore only be calculated in 3 patients, which was
decreased in one patient (0.3 cell divisions) and normal in the
remaining two patients (2.8 and 3.1 cell divisions; Figure 5A). Of
note, the absolute B-cell counts in these three patients were <1,
<1, and 3 per microliter blood. Patients with PAD had normal
copy numbers of intronRSS-Kde and lower numbers of KRECs (p
= 0.0085). Also, their B-cell replication history was higher than
in controls (median 4.063 vs. 3.550, p = 0.0268). Subsequently,
we focused on patients with non-infectious complications and
found lower KREC copy numbers as compared to patients with
the infections-only phenotype (p = 0.0453). Compared to aging
in healthy controls, patients with PAD show similar age-related
correlations to T- and B-cell replication (Figure S2).
The studies of the T-cell compartment in patients with XLA
showed normal TRG and TREC copy numbers, as well normal
replication history (Figure 5B). For patients with PAD, normal
TRG copy numbers, but decreased TREC counts and increased T-
cell replication history were found as compared to controls (both
p< 0.0001). There were no differences between patients with and
without non-infectious complications.
B- and T-Cell Replication in Dried Blood
Spots of Children With Down Syndrome
Newborn screening for T-cell and B-cell lymphopenia is highly
sensitive but has a poor specificity (35). Unfortunately, it is
currently not possible to determine which patients should be
referred urgently and for which patients a repeat screening test
should be requested. Quantification of intronRSS-Kde and TRG
copy numbers and calculation of the B- and T-cell replication
history could potentially be part of second-tier testing in
newborns with abnormal screening results to facilitate a risk
assessment. In a previous study we showed that newborns with
Down syndrome have lower numbers of KRECs and TRECs than
healthy controls (24), which we replicated here (Figures 6A,B).
Since DNA recovery from stored Guthrie cards is less predictable,
we corrected our results for DNA input by including a control
PCR targeting the albumin gene.
Children with Down syndrome have reduced intronRSS-Kde
and TRG copy numbers compared to healthy newborns, which
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TABLE 1 | Immunological and clinical characteristics of adults with inborn errors of immunity.
Patient
ID
Age at
analysis
(yr)
Sex Gene Mutation B-
cells#/µl
blood
T-cells/µl
blood
IgG at
diagnosis
(g/L)
IgA
(g/L)
IgM
(g/L)
Impaired
vaccination
response
Infectious complications Non-infectious complications
X-LINKED AGAMMAGLOBULINEMIA (XLA)
XLA-01 18 M BTK c.1257delG <1 3,148 N/A N/A N/A N/A None None
XLA-02 21 M BTK c.1257delG <1 1,652 N/A 0.1 0.1 N/A Pneumonia, bronchiectasis None
XLA-03 22 M BTK c.1257delG <1 1,770 N/A <0.1 <0.1 N/A Otitis, sinusitis, pneumonia None
XLA-04 24 M BTK c.1257delG 10 1,401 N/A 0.1 0.1 N/A Sinusitis, bronchiectasis, prostatitis None
XLA-05 * 24 M BTK c.1908+1G>C <0.1 1,497 N/A <0.1 <0.1 N/A Otitis, sinusitis, pneumonia Pre-B-ALL
XLA-06 26 M BTK c.1257delG <0.1 2,478 N/A <0.1 <0.1 N/A Otitis, sinusitis, pneumonia, bronchiectasis None
XLA-07 34 M BTK c.862C>T 1 625 N/A <0.1 <0.1 N/A Otitis, sinusitis, pneumonia None
XLA-08 49 M BTK c.1559G>A 3 801 N/A 0.1 0.1 N/A Otitis, sinusitis, pneumonia, bronchiectasis None
XLA-09 59 M BTK c.1787+71C>T <0.1 3,141 N/A <0.1 <0.1 N/A Otitis, sinusitis, pneumonia, asthma/COPD,
bronchiectasis
None
PAD
PAD-01 23 F N/A N/A 215 1,339 4.4 0.2 0.4 N/A Otitis, sinusitis Enteropathy
PAD-02 23 M N/A N/A 446 1,422 4.9 0.3 0.3 N/A Sinusitis ITP, AIHA, neutropenia, splenomegaly
PAD-03 24 F N/A N/A 17 736 <1.4 <0.15 <0.2 N/A Pneumonia, sinusitis, Arthritis, enteropathy
PAD-04 24 M N/A N/A 228 954 1.1 <0.1 <0.1 N/A Pneumonia, otitis, sinusitis, VZV None
PAD-05 25 M N/A N/A 230 1,381 2.2 <0.1 0.1 N/A Sinusitis, pneumonia Arthritis
PAD-06 26 M N/A N/A 467 3,355 N/A 0.6 0.3 Pneumococcal Bronchitis, sinusitis, pneumonia None
PAD-07 27 F N/A N/A 166 2,008 3.9 0.7 0.3 N/A Pneumonia, bronchitis Vitiligo
PAD-08 28 M N/A N/A 37 700 3.3 1 0.4 N/A Bronchitis, pneumonia Pulmonary nodules, colitis
PAD-09 29 F N/A N/A 144 1,982 5.2 0.3 0.5 Normal Asthma/COPD None
PAD-10 30 F N/A N/A 1,089 2,953 2.2 0.4 0.6 N/A Sinusitis Cytopenia
PAD-11 31 F N/A N/A 361 983 5.6 0.3 1.3 Normal Sinusitis, systemic viral infection, giardia Enteropathy
PAD-12 34 F N/A N/A 46 1,083 <1 <0.1 <0.1 N/A Otitis, sinusitis, pneumonia, bronchiectasis GLILD
PAD-13 35 F N/A N/A 222 646 2.0 0.1 0.1 Pneumococcal Sinusitis, giardia, asthma/COPD Enteropathy
PAD-14 37 M N/A N/A 78 981 4.1 0.1 0.4 Pneumococcal,
Hib
Otitis, sinusitis, pneumonia, systemic viral
infection, giardia, asthma/COPD, bronchiectasis
Granuloma, enteropathy
PAD-15 37 M N/A N/A 1.3 901 2.1 <0.1 <0.1 Pneumococcal Pneumonia, asthma, bronchiectasis, chlamydia ITP, eczema
PAD-16 40 F N/A N/A 202 1,038 5.2 1.5 0.9 Normal Sinusitis, pneumonia None
PAD-17 41 M N/A N/A 35 1,107 2.6 0.2 0.2 Pneumococcal Sinusitis, pneumonia, systemic viral infection, Granuloma, enteropathy
PAD-18 43 F N/A N/A 101 1,242 2.0 0.3 0.2 Pneumococcal Sinusitis, pneumonia Cytopenia
PAD-19 43 F N/A N/A 116 1,554 4.2 3.2 0.6 Pneumococcal Sinusitis, pneumonia Inflammatory tracheal stenosis
PAD-20 44 F N/A N/A 177 614 2.7 0.1 0.1 Pneumococcal Sinusitis, pneumonia, giardia Splenomegaly, enteropathy
PAD-21 44 M N/A N/A 91 834 0.6 0.0 0.2 N/A Sinusitis, pneumonia, bronchiectasis Splenomegaly, lymphadenopathy, granuloma,
enteropathy, arthritis
PAD-22 45 M N/A N/A N/A N/A 4.7 2 1.2 N/A None HUS
(Continued)
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TABLE 1 | Continued
Patient
ID
Age at
analysis
(yr)
Sex Gene Mutation B-
cells#/µl
blood
T-cells/µl
blood
IgG at
diagnosis
(g/L)
IgA
(g/L)
IgM
(g/L)
Impaired
vaccination
response
Infectious complications Non-infectious complications
PAD-23 46 M N/A N/A 228 870 0.6 0.1 0.1 Pneumococcal Otitis, sinusitis None
PAD-24 47 F N/A N/A 84 1,210 3.1 <0.1 <0.1 N/A Sinusitis, bronchitis, Colitis, autoimmunity
PAD-25 50 F N/A N/A N/A N/A 5.8 0.3 0.2 Pneumococcal Otitis, sinusitis, pneumonia None
PAD-26 52 F N/A N/A 96 678 3.8 0.9 0.8 N/A Bronchitis, sinusitis Pericarditis
PAD-27 52 F N/A N/A 193 1,329 5.2 0.8 1.3 pneumococcal Sinusitis, pneumonia None
PAD-28 52 M N/A N/A 195 473 3.2 0.3 0.2 Hib Sinusitis, pneumonia None
PAD-29 54 M N/A N/A 245 775 2.9 <0.1 0.1 N/A Sinusitis, pneumonia, asthma/COPD,
bronchiectasis
None
PAD-30 54 M N/A N/A 152 1,040 4.4 0.2 1.0 Pneumococcal,
Hib, diphtheria,
tetanus
Sinusitis, pneumonia Solid organ malignancy
PAD-31 54 F N/A N/A 373 1,473 5.4 1.6 0.3 Pneumococcal Bronchiectasis, sinusitis Hypothyroidism
PAD-32 54 F N/A N/A 95 631 N/A 0.2 0.4 N/A Viral pneumonia, otitis None
PAD-33 55 F N/A N/A 215 1,362 4.1 0.4 0.8 Normal Pneumonia Inflammatory tenosynovitis
PAD-34 55 F N/A N/A 138 1,214 4.8 0.8 1.4 Pneumococcal Otitis, sinusitis, pneumonia None
PAD-35 56 M N/A N/A 86 235 N/A <0.1 0.2 N/A Pneumonia, hepatitis, colitis AIHA, ITP, splenomegaly
PAD-36 60 F N/A N/A 119 1,408 5.9 0.7 1.3 N/A Sinusitis, otitis, pneumonia Hashimoto’s thyroiditis
PAD-37 62 F N/A N/A 204 1,229 5.6 1.3 0.3 Pneumococcal Sinusitis None
PAD-38 66 F N/A N/A 161 539 3.5 0.6 0.2 N/A Bronchitis, bronchiectasis, asthma None
PAD-39 67 F N/A N/A 191 1,844 4.6 0.6 2.9 Diphtheria Sinusitis, pneumonia, asthma/COPD Enteropathy, autoimmunity
PAD-40 73 F N/A N/A 154 1,345 3.3 0.3 0.3 N/A Sinusitis, asthma/COPD, bronchiectasis None
PAD-41 77 F N/A N/A 70 553 4.2 0.8 1.9 Diphtheria Systemic viral infection, bronchiectasis, ILD Solid organ malignancy, auto-immunity
PAD-42 82 M N/A N/A 13 727 N/A 0.6 0.2 N/A Otitis, sinusitis, pneumonia, bronchiectasis Cytopenia
Normal
range
190–550 1,090–
3,020
6.10–16.2 0.85–
4.99
0.35–
2.42
#Values of lymphocyte subsets and immunoglobulin levels below and above normal values are marked in bold and italic font, respectively. *Patient XLA-05 has been described before by van Zelm et al. (34).
AIHA, auto-immune hemolytic anemia; COPD, chronic obstructive pulmonary disease; GLILD, granulomatous-lymphocytic interstitial lung disease; Hib, Haemophilus influenza B; HUS, hemolytic-uremic syndrome; ILD, interstitial lung
disease; ITP, immune-mediated thrombocytopenia; VZV, varicella zoster virus; N/A, not available.
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FIGURE 5 | B-cell and T-cell replication histories in PAD patients. (A) intronRSS-Kde, KRECs and B-cell replication histories, and (B) TRG, TRECs and T-cell
replication history for healthy controls and patients with XLA (n = 9) and PAD (CVID and hypogammaglobinemia) with infections only (n = 14) and non-infectious
complications (n = 28) as determined from whole blood. Obtained values are shown in gray and undetectable values are shown in black; numbers indicated represent
detectable values, and only they were included for statistical analysis with the Mann-Whitney U-test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
is consistent with previous studies showing decreased absolute
B- and T-cell counts (Figures 6A,B) (36, 37). Subsequently, we
calculated the replication histories. In healthy newborns, B cells
have undergone a limited number of cell divisions (median 0.57)
and T cells show ∼5 cell divisions, which is consistent with
results from naive B- and T-cell subsets (Figure 6C) (13). In
comparison, newborns with Down syndrome showed a slightly
increased number of cell divisions in their B-cell compartment
than controls (0.885 vs. 0.57, p = 0.0082, Figure 6C). This
could be the result of compensatory proliferation as a result of
decreased bone marrow output or increased apoptosis (20, 38).
The number of cell divisions for T cells were similar between
children with Down syndrome and controls.
In addition to calculation of replication histories, the intron-
RSS and TRG assays could be applied as a follow-up test in
newborn screening settings to confirm or refute a positive finding
with the KREC and TREC assays, respectively. We calculated the
sensitivity and specificity of the intronRSS-Kde and TRG assays
in our cohort of children with Down syndrome, assuming the
KREC and TREC assays as the Gold standard and that values
below the 5th percentile of controls were abnormal. Based on
abnormal KREC results (“positive test results”), the sensitivity
and specificity of the intronRSS-Kde assay were 75 and 80%, and
for TRG to confirm an abnormal TREC result these were 45 and
97%. If used as a second tier test, the intron-RSS-Kde assay would
confirm the abnormal KREC in 75% of cases, and the TRG assay
would do so in 97% of abnormal TREC cases.
DISCUSSION
Here we demonstrate the development and application of a novel
multiplex TRG RQ-PCR assay and our TREC containing T-cell
Frontiers in Immunology | www.frontiersin.org 9 August 2019 | Volume 10 | Article 2084
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FIGURE 6 | B-cell and T-cell replication histories in neonates with Down syndrome. IntronRSS-Kde and KREC (A), and TRG and TREC (B) in healthy neonates and
children with Down syndrome, corrected for DNA input as determined from Guthrie cards. (C) B- and T-cell replication histories for healthy neonates and children with
Down syndrome. The Mann-Whitney U-test was used for statistical analysis.
line with biallelic TRG rearrangements enable the quantitative
analysis of T-cell replication in normal immunobiology as well
as immunodeficiency. By using this approach, we showed that
naive T-cell subsets of healthy controls have undergone a limited
number of cell divisions (<5) in contrast to antigen experienced
effector T cells (>10). Furthermore, we showed that patients with
PAD have an abnormal increase in both B- and T-cell replication
history. By applying these assays on dried blood spot samples of
healthy newborns, we showed that the intronRSS-Kde and TRG
coding joint assays showed similar reductions in number as the
TREC and KREC signal joint assays. Hence, the coding joint
assays could have a role in second-tier testing after screening has
identified abnormally decreased TREC and/or KREC levels.
We present a new approach for ex vivo quantification of in
vivo T-cell replication histories. A variety of DNA labeling and
intracellular lysine residues techniques have been used to study
T-cell replication (39–41). Most previously reported approaches
are limited to in vitro studies of human T-cell replication,
whereas our RQ-PCR assay can be utilized to quantify the in vivo
replication history. On the other hand, in vivo turnover of human
T cells can be addressed by deuterium incorporation (42, 43).
This has provided new insights into production and longevity of
T cells. Ideally, in vivo deuterium labeling will be combined with
ex vivo T-cell replication history analysis to obtain a full picture
of T-cell production, longevity and replication in humans.
The TRG assay quantifies coding joints of Vγ-Jγ gene
rearrangements and is therefore suitable as a means to quantify
T-cell input. As δREC-ψJα coding joints are removed from the
genome of developing T cells by Vα-Jα gene rearrangements,
these cannot be utilized as a genomic marker (23). Previous
studies have used other means to overcome this limitation
of the “missing coding joint”. The most notable are those in
which T cells or subsets have been FACS purified and a general
genomic marker was chosen for TREC quantification (e.g.,
albumin, TRAC or CD3G) (9, 44, 45). Limitations for such an
approach are the fact that each cell will contain 2 copies of these
genomic markers, whereas δREC-ψJα gene rearrangements are
found in less than half of TRA/D loci (30), with the remainder
of the TRD loci being deleted by rearrangements involving
other genetic elements (22). Moreover, sort-purification of T
cells can restrict large-scale analysis of samples as it is labor
intensive, costly and requires high cell numbers to yield sufficient
material for RQ-PCR. The TRG assay being T-cell specific and
detecting just under 1 allele/cell in αβT cells, i.e., very similar
to the frequency of δREC-ψJα gene rearrangements. Finally,
the combined use with our control cell line enables technical
correction for PCR efficiencies, which is needed to accurately
determine cell divisions.
As δREC-ψJα gene rearrangements are initiated relatively late
during thymocyte development, TREC measurement includes
the combined replication history of double positive and single
positive CD4 thymocytes, as well as homeostatic proliferation
in the periphery, but most likely not that of double negative
thymocytes prior to TCRβ selection (30, 44, 45). With the
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TRG-TREC approach, we quantified the replication history of
naive Th cells to be ∼5 cell divisions for the CD31+ subset and
∼6 for the CD31- subset. This is in line with the∼6 cell divisions
for naive CD4+ T cells from young adults previously reported
(44). In addition, it confirms earlier observations that the CD31+
subset is more enriched for TRECs and is likely enriched for
RTEs (46, 47).
The replication histories of naive CD8+ and CD4+ T cells
were very similar. In contrast, CD8+ Tcm had a much lower
average replication history than CD4+ Tcm. Hence, despite
their phenotypic similarity, this indicates that different processes
underlie their generation, i.e., with distinct levels of proliferation.
Alternatively, the CD8+ Tcm subset could be a mixture of
memory cells with more naive T cells that have not undergone
antigen-induced proliferation.
With normal aging, the total T-cell compartment remains
stable in size while naive subsets decrease and effector
populations increase (48, 49). This is reflected by stable TRG copy
numbers throughout life and decreasing TRECs with higher age
(32). As a result, the overall T-cell replication history increases
with age.
In our study, we have focused on immunodeficiencies that
are characterized by impaired antibody formation. Patients with
XLA have strongly decreased or undetectable intronRSS-Kde
copy numbers as well as KRECs. We calculated normal B-cell
replication histories for 2 out of 3 patients, which is in line
with previous findings (50). Normal T-cell replication history was
found in patients with XLA. This is consistent with the fact that
the BTK protein is normally not expressed in T cells of healthy
controls, and T-cell biology does not appear to be affected (51).
Patients with PAD are heterogeneous with regards to their
clinical presentations as well as immunologic investigations.
These conditions are classically thought to be primarily caused
by defective B-cell function. Nonetheless, a significant portion
of patients are found to have T-cell abnormalities, especially
showing decreased naive T-cell subsets (6, 52, 53). A study
from Kamae et al. showed that patients with CVID who have
decreased TRECs and KRECs are more likely to develop disease
related complications (i.e., infections, autoimmune diseases and
malignancies), warranting to consider a diagnosis of combined
immunodeficiency (CID) (33). Here, we have shown alterations
in the T-cell compartment of patients with PAD that confirm
that not only B-cell immunity is affected. Currently, our methods
do not allow for classification of patients with PAD in order to
identify an underlying (genetic) cause or help to assess the risk
for developing non-infectious complications. However, studying
the replication history in sorted T-cell subsets might give more
insight in the pathways that are affected in patients with PAD and
allow for new classification strategies that will assist in clinical
management of these patients. As the T-cell abnormalities were
not found in XLA patients, it is suggestive that in at least a
subset of PAD patients T-cell replication is affected intrinsically,
or as a result of additional inflammatory effects not present in
XLA patients.
We also demonstrated the potential to quantify the replication
history of T-cell subsets. In future studies, this could provide
new insights into Th-cell function. For example, Th17 cells
which have an important role in the etiology of a variety of
inflammatory conditions, including rheumatoid arthritis and
inflammatory bowel disease (54, 55). Furthermore, the effects
of immunosuppressive treatment could be studied to determine
whether normal states can be achieved and serve as a disease
monitoring feature. It should be noted that the calculation of
T-cell replication will be limited in several disease settings. In
cases of severe T-cell lymphopenia, the TREC and/or TRG
potentially will not generate a signal, similar to what we
observed for the KREC and intronRSS-Kde assays in our patients
with XLA. Furthermore, in extreme T-cell lymphoproliferations,
TRECs might be extremely diluted and unable to be detected
with the TREC assay. This will be especially true in case
of monoclonal proliferations, but potentially also in extreme
polyclonal proliferations, in parallel to the dilution of KRECs in
persistent polyclonal B-cell lymphocytosis (PPBL) (56).
Although newborn screening for T-cell and B-cell
lymphopenia is highly effective, at least 80% of newborns
with a positive test (reduced TRECs and/or KRECs) turn out to
be “false positives” and do not have SCID or XLA. Currently, all
abnormal results require drawing of a second blood sample for
immunophenotyping. Ideally, a large number of false positives
are identified using a second-tier DNA-based test. For example,
22q11 microdeletion syndromes and Down syndrome can be
identified in a reliable manner via dried blood spot samples
(24, 57). We were able to establish that our intronRSS-Kde
and TRG assays generate reliable results on dried blood spot
samples. These assays could be applied to samples from children
with abnormal TREC and/or KREC screening results, prior
to alarming their parents to request a second sample for
additional testing.
We here described the development of a novel combined
TRG coding joint RQ-PCR and δREC ψJα signal joint RQ-
PCR assay with a TREC control cell line, which together allow
reliable quantification of in vivo T-cell replication history. Our
approach has led to new insights in normal T-cell biology, aging
and immunodeficiency.Moreover, the high specificity of the TRG
and intronRSS-Kde assays to confirm an abnormal TREC and
KREC finding in neonates with Down syndrome shows a promise
for application of these assays as second tier test in newborn
screening. Still, extensive evaluation on large cohorts of neonates
with genetically-confirmed SCID or XLA will be required to
evaluate if application of these assays could reduce the number of
cases in which a second blood sample for verification of abnormal
results is required.
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